An internal standard for the quantification of anagrelide
Related Products
Unlabeled Version(s)
21411Anagrelide (hydrochloride)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Anagrelide-13C3

Item No. 33280

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6,7-dichloro-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one-2,3,5-13C3
Synonyms
  • BL 4162A-13C3
  • BMY 26538-01-13C3
Molecular Formula
C7[13C]3H7Cl2N3O
Formula Weight
259.1
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: soluble
SMILES
ClC1=C([13CH2]N([13CH2]2)C(N3)=N[13C]2=O)C3=CC=C1Cl
InChi Code
InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)/i3+1,4+1,8+1
InChi Key
OTBXOEAOVRKTNQ-WFHXKFHPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $173

    Add

    1 mg

    $308

    Add
    Product Description

    Anagrelide-13C3 is intended for use as an internal standard for the quantification of anagrelide (Item No. 21411) by GC- or LC-MS. Anagrelide is an inhibitor of phosphodiesterase 3 (PDE3; IC50 = 36 nM for the human platelet enzyme).1 It inhibits thrombopoietin-induced megakaryocytopoiesis of isolated human CD34+ progenitor cells (IC50 = 26 nM).2 Anagrelide reduces platelet aggregation induced by ADP, collagen, thrombin, or arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in isolated rabbit platelet rich-plasma (EC50s = 0.31, 0.08, 0.18, and 0.1 µg/ml, respectively).3 It inhibits platelet thrombus formation in a dog model of electrically induced carotid artery thrombosis when administered at doses ranging from 0.5 to 5 mg/kg.4 Formulations containing anagrelide have been used in the treatment of thrombocythemia.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Wang, G., Franklin, R., Hong, Y., et al. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br. J. Pharmacol. 146(3), 324-332 (2005).

    2. Hong, Y., Wang, G., Gutierrez del Arroyo, A., et al. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: Selectivity of anagrelide for the megakaryocytic lineage. Leukemia 20(6), 1117-1122 (2006).

    3. Fleming, J.S., and Buyniski, J.P. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb. Res. 15(3-4), 373-388 (1979).

    4. Fleming, J.S., and Buyniski, J.P. Anagrelide. New drugs annual: Cardiovascular drugs 277-294 (1983).